Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling.

4C8 is a new mouse anti-human CD34 monoclonal antibody (mAb), which recognizes class II CD34 epitopes and can be used for clinical hematopoietic stem/progenitor cell selection. In an attempt to improve its safety profiles, we have developed a humanized antibody of 4C8 by complementarity-determining region (CDR) grafting method in this study. Using a molecular model of 4C8 built by computer-assisted homology modelling, framework region (FR) residues of potential importance to the antigen binding were identified. A humanized version of 4C8, denoted as h4C8, was generated by transferring these key murine FR residues onto a human antibody framework that was selected based on homology to the mouse antibody framework, together with the mouse CDR residues. The resultant humanized antibody was shown to possess antigen-binding affinity and specificity similar to that of the original murine antibody, suggesting that it might be an alternative to mouse anti-CD34 antibodies routinely used clinically.

[1]  S. Kipriyanov,et al.  Generation and production of engineered antibodies , 2004, Molecular biotechnology.

[2]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[3]  Ya-jun Guo,et al.  Construction and characterization of a humanized anti‐human CD3 monoclonal antibody 12F6 with effective immunoregulation functions , 2005, Immunology.

[4]  J. Tso,et al.  Humanization and characterization of the anti‐HLA‐DR antibody 1D10 , 2001, International journal of cancer.

[5]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Huse,et al.  Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. , 1999, Journal of molecular biology.

[8]  D. Norman.  Mechanisms of Action and Overview of OKT3 , 1995, Therapeutic drug monitoring.

[9]  C. Chapman,et al.  Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency , 2005, Bone Marrow Transplantation.

[10]  A. Henry,et al.  Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Weizhu Qian,et al.  Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody. , 2007, Biochemical and biophysical research communications.

[12]  Ya-jun Guo,et al.  Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. , 2008, Biochemical and biophysical research communications.

[13]  R. Handgretinger,et al.  Selection of Stem Cells by Using Antibodies That Target Different CD34 Epitopes Yields Different Patterns of T‐Cell Differentiation , 2007, Stem cells.

[14]  A. Keating,et al.  Differential sensitivity of CD34 epitopes to cleavage by Pasteurella haemolytica glycoprotease: implications for purification of CD34-positive progenitor cells. , 1992, Experimental hematology.

[15]  R. Colvin,et al.  Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. , 1986, Transplantation.

[16]  G. Gaudernack,et al.  Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells , 1996, British journal of haematology.

[17]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Davis,et al.  Isolation and molecular characterization of the human CD34 gene. , 1992, Blood.

[19]  G. Boulianne,et al.  Production of functional chimaeric mouse/human antibody , 1984, Nature.

[20]  M. Fackler,et al.  Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. , 1984, Journal of immunology.

[21]  J Saldanha,et al.  Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.

[22]  V. Roberts,et al.  Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. , 1996, Journal of immunology.

[23]  CD34: structure, biology, and clinical utility. , 1996, Blood.

[24]  K. Shitara,et al.  Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions , 2001, Cancer Immunology, Immunotherapy.

[25]  N. Schmitz,et al.  Hematopoietic stem cell transplantation for hematological malignancies in Europe , 2003, Leukemia.

[26]  N. Tsurushita,et al.  Design of humanized antibodies: from anti-Tac to Zenapax. , 2005, Methods.

[27]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A S Dion,et al.  Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. , 1995, Molecular immunology.

[29]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[30]  W. Weimar,et al.  The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients. , 1990, Transplantation proceedings.

[31]  C. Peters,et al.  Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines , 2003, Bone Marrow Transplantation.